Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q53GS9
UPID:
UBP39_HUMAN
Alternative names:
SAD1 homolog; U4/U6.U5 tri-snRNP-associated 65 kDa protein
Alternative UPACC:
Q53GS9; A8K086; B3KM40; B4DHT4; D6W5L4; G5E9H0; Q6NX47; Q96RK9; Q9BV89; Q9H381; Q9P050; Q9Y310
Background:
Ubiquitin carboxyl-terminal hydrolase 39, also known as SAD1 homolog and U4/U6.U5 tri-snRNP-associated 65 kDa protein, is pivotal in cellular processes such as antiviral response, epithelial morphogenesis, DNA repair, and B-cell development. It plays a crucial role in pre-mRNA splicing, immunoglobulin gene rearrangement, cytokinesis, apoptosis, and DNA damage response by interacting with various cellular components.
Therapeutic significance:
Understanding the role of Ubiquitin carboxyl-terminal hydrolase 39 could open doors to potential therapeutic strategies.